← All trials
NCT04122755
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2019
- Primary completion
- Sep 30, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alar Pharmaceuticals Inc.Lead sponsor
- Innovative Clinical Research, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.